source
- Setbacks in two heart disease trials raise questions about future cardiovascular drug researchA recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…
- Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinismRezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…